Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
German men need approval for stays abroad under military service law - 2She's been a Bond girl and a mutant. Now she's grappling with Hollywood's obsession with 'eternal youth.'
- 3Figure out How to Get the Most Familiar Drive for Seniors in SUVs
- 4Sixteen Kenyans missing in Russia after army recruitment
- 5Figure out How to Modify Your Pre-assembled Home for Greatest Solace and Stylish Allure
- Sea Ice Hits New Low in Hottest Year on Record for the Arctic
- Bring tissues and skip the mascara: The movie that's making theater-goers sob uncontrollaby
- Collierville residents with no power as temperatures plunge
- Poll: Only 25% of Americans think Trump has 'followed through' on his promise to release the Epstein files
- 1st-ever disease gene fix, Alzheimer's blood test: 7 medical breakthroughs in 2025
- Why Tourists May Want To Reconsider Traveling To This Popular Spot In Italy In 2026
- The Job of Attorneys: It is Important to Comprehend When Legitimate Help
- $1,000 bribes, Mormon momfluencer mixers and making content to get plastic surgery: The wildest things I learned reporting my book
- How Seniors Can Use Refunds and Motivators to Purchase a Hyundai Ioniq EV
